NIKA
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | 0.00 | $0 | -$13,359 |
| 2025 Q4 | 0.00 | $0 | -$38,858 |
| 2025 Q3 | 0.00 | $0 | -$9,329 |
| 2025 Q2 | 0.00 | $0 | -$18,522 |
| 2025 Q1 | 0.00 | $0 | -$12,945 |
| 2024 Q4 | 0.00 | -$156 | -$12,452 |
| 2024 Q3 | 0.00 | $0 | $396,437 |
| 2024 Q2 | -0.00 | $156 | -$373,059 |